1,028 results on '"G. Gandaglia"'
Search Results
2. PIONEER consensus on clinician reported outcome measurements
3. PIONEER’s operational definitions: Harmonising clinical characteristics and phenotypes data of prostate cancer patients
4. Initial steps of an online search tool development for diagnostic and prognostic factors in prostate cancer
5. Multiparametric MRI of the prostate significantly underestimates tumor volume of small visible lesions. Implications for tailored focal therapy approaches
6. Association between BRCA 1/2 polymorphisms and disease aggressiveness in a prospective cohort of prostate cancer patients undergoing radical prostatectomy
7. How can we increase the positive predictive value of PIRADS 4 and 5 lesions at mp-MRI? Development of a novel prediction tool relying on a large, multi-institutional series
8. The inverse correlation between obesity and mortality in patients with metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials
9. Are men with low risk prostate cancer but high pirads score lesions at mp-MRI still candidate for active surveillance? Results from a large, multi-institutional radical prostatectomy series
10. Initial negative multi-parametric MRI with concomitant negative biopsy: Are true negative findings confirmed over time? Results from a single institution series
11. Age and Gleason score upgrading between prostate biopsy and radical prostatectomy. Is this still true in the mp-MRI era?
12. The added value of concomitant systematic biopsy in predicting biochemical recurrence after radical prostatectomy in patients with prostate cancer diagnosed by MRI-targeted biopsy
13. Should we target all visible areas at mpMRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
14. Can we improve our ability to assess primary tumor stage of prostate cancer in patients with MRI-visible lesions? development and external validation of a novel T-stage classification based on clinical and MRI findings
15. Can multiparametric MRI improve our ability to predict early biochemical recurrence after radical prostatectomy in contemporary patients? results from a multi-institutional analysis
16. Focal therapy for prostate cancer: do apical lesions correlate with worse outcomes?
17. Changing patterns and predictors of salvage radiation therapy use over time in patients treated for post-prostatectomy biochemical recurrence: a trend analysis over a 20-year period from a multi institutional series
18. Is focal ablation as effective as hemi-ablation? analysis of treatment patterns over 12 years from a high volume centre for focal therapy
19. Predicting toxicity-related Docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer using open phase 3 trial data
20. Prognostic value of high PIRADS score lesions at mp-MRI of the prostate in men with low risk prostate cancer managed with active surveillance. results from a single institution series
21. The relationship between percentage PSA reduction and rate of failure after focal therapy for prostate cancer
22. Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: a stage-specific analysis from a large multi-institutional series
23. Cure without toxicity: development of a novel model predicting trifecta outcomes after salvage radiation therapy for recurrent prostate cancer after radical prostatectomy
24. A positive PSMA PET/CT Predicts more aggressive disease progression in patients with biochemical recurrence after radical prostatectomy
25. Patient selection is key for salvage surgery in prostate cancer: EAU guidelines-compliant and non-compliant patients show different outcomes
26. Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial
27. Long-term outcomes of clinically node-positive prostate cancer patients treated with radical prostatectomy as part of a multimodal treatment: patterns of recurrence and impact on competing-risk mortality
28. Association between the extent of lymph node dissection and severe toxicity in men with prostate cancer treated with post-prostatectomy radiation therapy: results from a large multi-institutional series
29. Radical prostatectomy versus radiotherapy in M1a and low volume M1b prostate cancer patients: an indirect comparison with the STAMPEDE trial arm H
30. The impact of persistently elevated PSA levels on progression and survival of patients undergoing cytoreductive radical prostatectomy for oligometastatic prostate cancer
31. Patterns of clinical recurrences after salvage lymph node dissection for lymph-node recurrent prostate cancer and their impact on oncological outcomes. the importance of patient stratification for tailored post-operative treatments
32. Performance characteristics of PET/CT scan in men treated with salvage lymph node dissection for recurrent prostate cancer: a per patient analysis with pathological confirmation according to each area of dissection
33. A prospective, randomized, phase 3 trial assessing the impact of Early Dorsal Venous Complex (EDVC) ligation on urinary continence recovery after robot-assisted radical prostatectomy. results of an interim analysis on early post-operative outcomes
34. External validation of the 2019 Briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection
35. The relative drop of PSA values after androgen deprivation therapy is a useful parameter to select the best candidate for cytoreductive radical prostatectomy among patients with oligometastatic prostate cancer: an external validation study
36. What is the optimal surgical template for salvage pelvic lymph node dissection in patients with pelvic lymph-node recurrent prostate cancer? results from a large, multi-institutional series
37. Persistently elevated prostate-specific antigen after salvage lymph node dissection and its impact on long-term oncological outcomes. the importance of an extensive, multi-modal approach
38. Anatomical prostate mpMRI features and continence recovery after robot assisted radical prostatectomy: is there something beyond membranous urethral length? results from a large, multi-institutional cohort
39. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: results from the national cancer database
40. No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: interim results from the PURE01 study
41. Impact of molecular subtyping and immune infiltration on response and outcome following neoadjuvant pembrolizumab (pembro), versus neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer
42. Can multiparametric MRI improve our ability to predict early biochemical recurrence after radical prostatectomy in contemporary patients? Results from a multi-institutional analysis
43. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: Results from the national cancer database
44. How can we increase the positive predictive value of PIRADS 4 and 5 lesions at mp-MRI? Development of a novel prediction tool relying on a large, multi-institutional series
45. When is mp-MRI reliable in predicting extra-prostatic extension in prostate cancer patients treated with radical prostatectomy? Results from a large, multi-institutional series
46. No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: Interim results from the PURE01 study
47. Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: A stage-specific analysis from a large multi-institutional series
48. Assessing the impact of salvage radiation therapy field after radical prostatectomy: A long-term analysis from a large multi-institutional series
49. Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter study
50. The relationship between percentage PSA reduction and rate of failure after focal therapy for prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.